Trial Profile
A phase III trial to evaluate the safety and efficacy of the combination regimen of nivolumab and ipilimumab in treatement-naive patients with renal cell carcinoma
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2014
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 04 Jul 2014 New trial record